Owkin is a biotechnology company focused on leveraging AI to advance personalized medicine. The company's core activities encompass multimodal patient data analysis, and AI-enhanced drug discovery, development, and diagnostics. Owkin's research platform facilitates collaborative research across data scientists, clinicians, academic researchers, and pharmaceutical companies, while ensuring data privacy by allowing patient data to remain within hospital infrastructure. It has global reach with locations in cities like Boston, New York, London, Paris, Nantes, and Geneva.
Key customers and partnerships
Owkin has collaborated with major biopharmaceutical firms like Sanofi (November 2021), Bristol Myers Squibb (BMS) (June 2022), and Merck Sharp & Dohme (MSD) (December 2023), focusing on AI drug discovery, development, and diagnostics.
Funding and financials
In November 2021 , Owkin raised USD 180 million in Series B funding from Sanofi. The company was valued at more than USD 1 billion at the time of the funding. The funds were used to accelerate the company’s histology and genomic cancer database.
Earlier in June 2022, the company raised USD 80 million as part of a research collaboration with BMS. The proceeds were used to develop its AI-powered platform for clinical trial design and expand the disease indications that can be explored using the platform.
No investor data is available
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.